Latest Breaking News On - Stijn van rompay - Page 11 : comparemela.com

Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainable Growth Strategy and Support of Social Well-Being for its Employees

Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainable Growth Strategy and Support of Social Well-Being for its Employees
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Waals gewestParkand noshaqStijn van rompayHyloris pharmaceuticals sa euronext brusselsHyloris pharmaceuticalsWall streetEuronext brusselsVan rompayChief executive officer

Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update

01.09.2022 - - On track to broaden product pipeline to meet a target portfolio of 30 programs by 2024- Continued commercial rollout of Sotalol IV in US and Maxigesic IV - Focused entry into US market with Maxigesic IV for non-opioid pain treatment; continuing .

United statesVulvovaginal candidiasisVan rompayStijn van rompayAlter pharma groupHyloris pharmaceuticals sa euronext brusselsHyloris pharmaceuticalsDrug administrationTranexamic acid oral mouthEuronext brusselsChief executive officerUnited states foodComplete response letterDevelopments relatedAcid oral mouth rinseRecurrent vulvovaginal candidiasis

Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures

20.07.2022 - Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures HY-004 provides a new treatment alternative for use in patients on anti-coagulant therapies undergoing . Seite 1

Stijn van rompayHyloris pharmaceuticals sa euronext brusselsEuronext brusselsTranexamic acid oral solutionChief executive officer

Hyloris Provides Additional Information on U S FDA Review of NDA Application for the Registration of Maxigesic IV®

Hyloris Provides Additional Information on U S FDA Review of NDA Application for the Registration of Maxigesic IV®
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesStijn van rompayHyloris pharmaceuticals sa euronext brusselsHyloris pharmaceuticalsDrug administrationEuronext brusselsNew drug applicationComplete response letterChief executive officer

US FDA seeks more information on Maxigesic IV® application

US FDA seeks more information on Maxigesic IV® application
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Stijn van rompayHyloris pharmaceuticals sa euronext brusselsHyloris pharmaceuticalsDrug administrationWall streetEuronext brusselsComplete response letterChief executive officer